Patient support and product assistance

Novo Nordisk offers comprehensive support for patients and caregivers. Talk with a Novo Nordisk Representative about the variety of resources available to help your patients live well with hemophilia.

Friends with hemophilia A sitting on the beach


Malcolm, 19 years old; Dylan, 24 years old; and David, 22 years old, live with hemophilia A


 



 

Co-pay assistance program

Lowers the out-of-pocket cost of Novoeight® for your eligible patients


 



 

Novoeight assistance and co-pay support.

Product assistance

See how Novo Nordisk can help him get the treatment he needs.


 



 

NovoSecure™, a personalized patient support program from Novo Nordisk

Novo Nordisk product usage is not an eligibility requirement of NovoSecure™.

NovoSecure™

Learn how NovoSecure™, a patient support program from Novo Nordisk, may help your patients get where they want to be, regardless of their choice of treatment.


 



 

Novoeight Satisfaction Guarantee

Novoeight® Satisfaction Guarantee

Check out our Satisfaction Guarantee and see just how confident we are in Novoeight®.


 



 

NovoSecure™ patient support program website

Patient support

Through the NovoSecure™ website, your patient can create a personal dashboard and receive customized content and tools, regardless of his choice of treatment, to help him manage life with hemophilia.


 



 

team8 group photo

Share patient stories

Members of the community living with hemophilia A and treating with Novoeight® share their stories. Learn how they are giving back to the hemophilia community.


 



 

Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.
 

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.


Please click here for Novoeight® Prescribing Information.

Novo Nordisk Hemophilia & Rare Bleeding Disorders (RBD) Co-pay Assistance Program

Details of Offer, Including Restrictions on Eligibility and Other Limitations
With the Novo Nordisk Co-pay Assistance Program, you may receive up to $12,000 per year toward your co-pay for Novo Nordisk Hemophilia and Rare Bleeding Disorder products.

You are eligible to apply for the Novo Nordisk Hemophilia & RBD Co-pay Assistance Program if you:

  • Have hemophilia A and have been prescribed an appropriate Novo Nordisk factor treatment; OR
  • Have congenital hemophilia A or B with an inhibitor, congenital FVII deficiency, Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, or acquired hemophilia and have been prescribed an appropriate Novo Nordisk factor treatment; OR
  • Have FXIII A-subunit deficiency and have been prescribed an appropriate Novo Nordisk factor treatment; AND
  • Have private/commercial insurance only

Restrictions and Limitations: You are not eligible if prescriptions are paid by any state or federally funded programs, including, but not limited to, Medicare, Medicaid, Medigap, VA, DOD, or TRICARE, or where prohibited by law. Offer not valid for prescriptions reimbursed in full by any third party payor. Offer limited to 1 card per person. Offer void where taxed, restricted, or prohibited. Offer only good in the U.S.A. Eligibility is restricted to individuals; no clubs, groups, or organizations. This savings card is not transferable and is not insurance. When you use the Novo Nordisk Hemophilia & Rare Bleeding Disorders Co-pay Assistance Card, you are certifying that you understand the program rules, terms, and conditions and that you will comply with them.

Offer excludes full cash-paying customers. You must be enrolled in a commercial insurance plan.

How to use the Novo Nordisk Co-pay Card: You must present the card to the pharmacist along with your prescription to participate in this program. You are not eligible for these savings offers if prescriptions are paid by any state or federally funded programs, including but not limited to Medicare, Medicaid, Medigap, VA, DOD, or TRICARE, or where prohibited by law. Each time you use this card, you are certifying that you understand the program rules, terms, and conditions and that you will comply with them. Please deduct the amount of the discount from any claim for reimbursement submitted to your insurance company or plan. If you have any questions regarding your eligibility or benefits, need a replacement card, or if you wish to discontinue your participation, call 1-844-NOVOSEC (1-844-668-6732) Monday-Friday, 8:00 am to 8:00 pm ET.